ATPase family AAA domain containing 3A is an anti-apoptotic factor and a secretion regulator of PSA in prostate cancer
ATPase family AAA domain containing 3A is an anti-apoptotic factor and a secretion regulator of PSA in prostate cancer
复制标题
DOI：
10.3892/ijmm.2011.670
复制
发表时间：
2011-07-01
影响因子：
5.4
通讯作者：
Lee, Meng-Chih
中科院分区：
文献类型：
--
作者：
Huang, Kuo-Hsuan;Chow, Kuan-Chih;Lee, Meng-Chih
为探讨ATP酶家族AAA结构域3A（ATAD3A）在前列腺癌（PCa）中的临床应用价值，采用免疫组织化学方法检测了86例中国人和183例美国人前列腺癌组织芯片标本中ATAD3A的表达。通过体外实验测定ATAD 3A对前列腺特异性抗原（PSA）表达和PCa细胞系耐药性的影响。ATAD3A在86例中国患者样本中的74例（86.0%）和183例美国患者样本中的145例（79.2%）中检出。两组患者ATAD3A表达无差异。在体外，ATAD3A表达的沉默降低PSA分泌和顺铂耐药性，表明ATAD3A与前列腺癌的PSA分泌和耐药性相关。
In order to investigate the clinical value of ATPase family AAA domain containing 3A (ATAD3A), a potential anti-apoptotic factor in prostate cancer (PCa), immunohistochemistry was used to measure ATAD3A expression in pathological specimens from 86 Chinese patients and in 183 tissue-array samples from American patients. The effect of ATAD3A on the expression of prostate specific antigen (PSA) and drug resistance in PCa cell lines was determined by in vitro experiments. ATAD3A was detected in 74 of 86 (86.0%) Chinese specimens and in 145 of 183 (79.2%) American patient samples. No difference was found in ATAD3A expression between these two patient groups. In vitro, silencing of ATAD3A expression reduced PSA secretion and cisplatin resistance, suggesting that ATAD3A was associated with PSA secretion and drug resistance in PCa.